Furthermore, combination therapy reduced 5-FU IC50 from 7.473 ug/ml to 2.482 ug/ml, indicating that STAT6 silencing could raise the chemosensitivity of CRC cells to 5-FU treatment in this cell line. Here, STAT6 is linked to colorectal carcinoma.